CYLD and HCC: When Being Too Sensitive to Your Dirty Neighbors Results in Self-Destruction  by Font-Burgada, Joan et al.
Cancer Cell
PreviewsCYLD and HCC: When Being Too Sensitive
to Your Dirty Neighbors Results in Self-DestructionJoan Font-Burgada,1 Ekihiro Seki,2 and Michael Karin1,*
1Laboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology
2Department of Medicine
School of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA
*Correspondence: karinoffice@ucsd.edu
DOI 10.1016/j.ccr.2012.05.034
Hepatocellular carcinoma is the outcome of ongoing cycles of cell death and regeneration in chronic liver
disease. In this issue of Cancer Cell, Nikolaou et al. show that the deubiquitinating enzyme CYLD is critical
for controlling the balance between hepatocyte loss, regeneration, and malignant progression.The liver is the quintessential regenerative
organ in mammals as first documented in
the Greek mythology. It has been molded
through evolution to endure extreme chal-
lenges by environmental pollutants, toxic
metabolites, infections, and all kinds of
cellular stress. The liver is equipped with
an astonishing capacity for cellular repo-
pulation even after massive cell death.
Despite the obvious benefits of these
regenerative properties, they come at a
high cost. Chronic liver injury and the sus-
tained regeneration it induces provide the
perfect breeding grounds for one of the
deadliest cancers, hepatocellular carci-
noma (HCC). Chronic liver disease is
supported and sustained by unresolved
fibrotic and inflammatory responses. It is
in this context where NF-kB signaling
has acquired a title role in the liver cancer
field despite its Janus-like character.
NF-kB signaling in Kupffer cells and
other immune cell types is critical in
propagation of liver inflammation. How-
ever, hepatocyte-specific NF-kB defi-
ciency caused by ablation of either IkB
kinase b (IKKb) or its regulatory subunit
IKKg/NEMO can either augment chemi-
cally induced liver carcinogenesis (Maeda
et al., 2005) or lead to spontaneous liver
damage, inflammation, and tumorigen-
esis (Luedde et al., 2007). Inactivation of
hepatocyte NF-kB results in critical over-
activation of JNK and ablation of Jnk1 in
IkkbDhep mice prevents enhanced sus-
ceptibility to hepatic carcinogens (Sakurai
et al., 2006). In addition, defective expres-
sion of IKKg/NEMO and TAK1 also results
in spontaneous tumorigenesis with per-
sistent JNK activation (Luedde et al.,
2007; Inokuchi et al., 2010; Bettermann
et al., 2010). Treatment of IkkbDhep and
Ikkg/NemoDhep mice with an antioxidantor ablation of TnfrI in Tak1Dhep mice sup-
pressed JNK over-activation and HCC
formation. These results underscore that
HCC formation in these mice is caused
mainly by compensatory hepatocyte pro-
liferation following massive hepatocyte
death with enhanced reactive oxygen
species production and JNK activation
due to TNF over-production combined
with loss of protective NF-kB activity
and expression of antioxidant proteins.
Paradoxically, however, NF-kB is a key
driver of spontaneous HCC development
in Mdr2/ mice. Indeed, inhibition of
NF-kB or titration of TNF in these mice in-
hibited HCC development (Pikarsky et al.,
2004). In this issueofCancerCell, Nikolaou
et al. (2012) show that specific deletion of
the cylindromatosis tumor suppressor
gene (Cyld) in hepatocytes results in
HCC formation. Surprisingly, the authors
found a procarcinogenic effect for TAK1,
NF-kB, and JNK in CyldDhep mice.
Nikolaou et al. (2012) deleted Cyld
specifically in hepatocytes to analyze its
effects on the liver. CYLD is a negative
regulator of NF-kB signaling, being a key
deubiquitinase that removes K63-linked
ubiquitin chains from several key effectors
of the pathway, including TAK1 and IKKg/
NEMO. Since some of these effectors
control the activation of MAP kinases
(MAPK), the absence of CYLD also results
in upregulation of MAPKs, including JNK.
When CyldDhep mice are born, their liver
appears normal. However after 25 days
of age, periportal hepatocytes start dying.
The authors demonstrate that this sponta-
neous cell death is due to prolonged JNK
activation. This finding prompted Niko-
laou and colleagues (2012) to identify the
upstream effector responsible for JNK
activation. Because TAK1 activation re-Cancer Cellquires K63-linked ubiquitination and
CYLD counteracts this modification in
CYLD-deficient livers, TAK1 is spontane-
ously activated. Although previous re-
ports showed that deletion of TAK1 in
hepatocytes also results in spontaneous
cell death, chronic TAK1 activation leads
to sustained JNK activation which eventu-
ally promotes cell death even in the
presence of NF-kB. To better investigate
this point, the authors generated Cyld
and Tak1 double knockout mice. These
animals exhibit a complete reversion of
periportal hepatocyte death accompa-
nied by a reduction in fibrosis and JNK
activity, similar to those found in Tak1Dhep
single mutants. Remarkably, periportal
cell death and fibrosis in CyldDhep mice,
with time, are extended toward the central
vein region. This is accompanied by
increased infiltration of inflammatory cells
and TNF production on postnatal day 45
when hepatic NF-kB activation becomes
detectable. This result prompted the
authors to hypothesize that there are
two different phases in the life of the
CYLD-deficient liver. Initially, CYLD-
devoid periportal hepatocytes suffer
spontaneous cell death, provoking a
second phase of injury expansion medi-
ated by immune cells through TNF-medi-
ated death receptor signaling. Ablation of
the Tnfr1 gene in CyldDhep mice demon-
strated that expansion of the damage is
TNF-dependent, but the persistent peri-
portal damage pinpoints the TNF-inde-
pendent nature of the initial defect.
Progressive and sustained liver injury
and fibrosis eventually lead to develop-
ment of HCC after 12 months of age.
The work of Nikolaou et al. (2012) offers
novel insights into the role of NF-kB
signaling in liver homeostasis and21, June 12, 2012 ª2012 Elsevier Inc. 711
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Previewsdisease. So far, most of our knowledge of
NF-kB signaling in liver pathophysiology
is derived from studies in which NF-kB
activation or activity is inhibited. The
authors used the opposite approach
trying to activate NF-kB by removing
CYLD. Surprisingly, only hepatocytes in
close vicinity to the portal triad suffer
spontaneous apoptosis but only after
postnatal day 10, arguing against a cell
autonomous promotion of cell death in
the absence of CYLD. If this is the case,
what triggers the periportal cell death
from postnatal day 10 onward? Perti-
nently, the authors point to commensal
bacteria in the gut. During embryogenesis
and shortly after birth, the gut is sterile and
thus, the portal circulation to the liver is
free of bacteria or microbial products.
However, after the first postnatal days,
the microflora start colonizing the gut,
and an influx of microbial components,
such as lipopolysaccharide (LPS) reaches
the liver. At this point, if the hepatocytes
are devoid of CYLD, an important attenu-
ator of NF-kB signaling, they misinterpret
the amount of LPS and other TLR agonists
to which they are exposed. Invariably,
this would lead to programmed cell death
in hepatocytes that overreact to TLR
agonists. Of note, CYLD is expressed in
a gradient, being higher in the periportal712 Cancer Cell 21, June 12, 2012 ª2012 Elsregion and lower close to the central
vein, supporting an important role for
CYLD in signal fine-tuning in the area
where TLR agonist concentration can
fluctuate the most. New investigations
using germ-free CyldDhep mice would
provide an important test of this hypoth-
esis. After this initial trigger, the CYLD-
deficient liver starts on a self-destruction
spiral. The initial death of periportal hepa-
tocytes triggers an inflammatory re-
sponse mediated by Kupffer cells. These
cells produce TNF and other death cyto-
kines that act on hyper-responsive hepa-
tocytes, causing more cell death and
more inflammation, eventually enhancing
compensatory proliferation. Interestingly,
Dapito et al. (2012) recently reported that
HCC promotion is affected by intestinal
microbiota through TLR4 signaling in the
liver. Considering that in several human
liver diseases there is an increase in intes-
tinal permeability and consequently an
increase of microbial components in the
portal circulation, the studies of Nikolaou
et al. (2012) and Dapito et al. (2012) estab-
lish a new paradigm in liver disease in
which intestinal microbiota can determine
hepatocyte cellular survival and death.
Thus, the intestinal barrier and com-
mensal microflora further influence the
NF-kB-JNK interplay that is alreadyevier Inc.known to play a central role in the control
of liver pathophysiology.REFERENCES
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Data from human tumors and mouse models suggest that tetraploidy, one example of polyploidy, can pro-
mote tumorigenesis. In this issue of Cancer Cell, Davoli and De Lange make important connections between
tetraploidy, tumorigenesis, and telomere crisis—a common event during the development of human cancers.Organism-level polyploidy-increasedcom-
plete sets of chromosomes are very
frequent in plants and are often found ininsects, fish, and amphibians. Genome
doublings are less common in metazoans,
but at least two tetraploidization eventsare thought to have occurred during the
evolution of vertebrates. Although still
debated, it has been proposed that during
